Welcome to our dedicated page for Benitec Biopharm SEC filings (Ticker: BNTC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Decoding Benitec Biopharma’s gene-silencing breakthroughs inside a 10-K or 8-K can feel like wading through lab notebooks. Clinical timelines, ddRNAi patent tables, and R&D expenses sprawl over hundreds of pages, while Benitec Biopharma insider trading Form 4 transactions surface at unpredictable hours. Stock Titan answers the problem by pairing real-time EDGAR feeds with AI that translates biotech jargon into plain language you can act on.
Need the next cash-runway update? Our platform flags it the moment a Benitec Biopharma quarterly earnings report 10-Q filing drops. Curious whether executives are adding shares before a BB-301 trial read-out? Receive instant alerts on Benitec Biopharma Form 4 insider transactions real-time. Each document arrives with an AI-powered summary that highlights pipeline milestones, licensing revenue, and risk factors—Benitec Biopharma SEC filings explained simply.
Explore every filing type in one place:
- 10-K: R&D spend, patent life, and Benitec Biopharma annual report 10-K simplified
- 10-Q: quarter-over-quarter trial costs and Benitec Biopharma earnings report filing analysis
- 8-K: clinical data releases with Benitec Biopharma 8-K material events explained
- DEF 14A: Benitec Biopharma proxy statement executive compensation decoded
- Form 4: Benitec Biopharma executive stock transactions Form 4 tracked to the minute
Whether you’re benchmarking cash burn or understanding Benitec Biopharma SEC documents with AI, Stock Titan condenses complexity into clear insights, so you spend time on decisions, not documentation.
Janus Henderson Group plc and its affiliate Janus Henderson Biotech Innovation Master Fund Ltd report beneficial ownership stakes in Benitec Biopharma Inc. Janus Henderson Group is reported to beneficially own 2,902,794 shares, equal to 11.3% of the common stock, with shared voting and shared dispositive power over those shares. The Biotech Innovation Master Fund is reported to beneficially own 2,193,481 shares, equal to 8.6% of the common stock, also held with shared voting and dispositive power.
The filing includes an explicit certification that the securities are held in the ordinary course of business and were not acquired for the purpose of changing or influencing control of the issuer. The filing identifies the reporting persons as an investment adviser/holding company and an investment vehicle.
Janus Henderson Group plc and an affiliated fund report beneficial holdings in Benitec Biopharma Inc. common stock (CUSIP 08205P209). The filing shows Janus Henderson Group plc with 25,600,210 shares of shared voting and dispositive power, representing 11.3% of the class. An affiliated vehicle, Janus Henderson Biotech Innovation Master Fund Ltd, reports 2,193,481 shares (shared voting and dispositive power), representing 8.6%. The schedule includes a certification that the securities were acquired in the ordinary course of business and a power of attorney executed by Janus Henderson Group plc authorizing named attorneys-in-fact to file required ownership reports.
FAQ
What is the current stock price of Benitec Biopharm (BNTC)?
What is the market cap of Benitec Biopharm (BNTC)?
